RefleXion Holds Initial Close of $105M Funding


RefleXion, a Hayward, CA-based therapeutic oncology company, raised $105M in funding.

The round was led by The Rise Fund, with participation from Ally Bridge, Pfizer Ventures and Johnson & Johnson Innovation (JJDC Inc.), T.Rowe Price Associates, Inc., Venrock, Catalio and Hillenbrand.

The company intends to use the funds to extend commercialization of its SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease.

Led by Todd Powell, president and chief executive officer, RefleXion is a therapeutic oncology company commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to multiple tumors. It is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers. The RefleXion X1 is also cleared for image-guided external-beam radiotherapy for solid tumors located anywhere in the body.